The/DT
Impact/JJ
of/IN
Transposable/JJ
Elements/NNS
in/IN
Genome/NN
Evolution/NN
and/CC
Genetic/JJ
Instability/NN
and/CC
Their/PRP$
Implications/NNS
in/IN
Various/JJ
Diseases/NNS
./.
====================
Approximately/RB
45/CD
%/NN
of/IN
the/DT
human/JJ
genome/NN
is/VBZ
comprised/VBN
of/IN
transposable/JJ
elements/NNS
(/(
TEs/NNS
)/)
./.
====================
Results/NNS
from/IN
the/DT
Human/JJ
Genome/NN
Project/NN
have/VBP
emphasized/VBN
the/DT
biological/JJ
importance/NN
of/IN
TEs/NNS
./.
====================
Many/JJ
studies/NNS
have/VBP
revealed/VBN
that/IN
TEs/NNS
are/VBP
not/RB
simply/RB
``/CD
junk/NN
''/CD
DNA/NN
,/,
but/CC
rather/RB
,/,
they/PRP
play/VBP
various/JJ
roles/NNS
in/IN
processes/NNS
,/,
including/VBG
genome/NN
evolution/NN
,/,
gene/NN
expression/NN
regulation/NN
,/,
genetic/JJ
instability/NN
,/,
and/CC
cancer/NN
disposition/NN
./.
====================
The/DT
effects/NNS
of/IN
TE/NN
insertion/NN
in/IN
the/DT
genome/NN
varies/VBZ
from/IN
negligible/JJ
to/TO
disease/NN
conditions/NNS
./.
====================
For/IN
the/DT
past/NN
two/CD
decades/NNS
,/,
many/JJ
studies/NNS
have/VBP
shown/VBN
that/IN
TEs/NNS
are/VBP
the/DT
causative/JJ
factors/NNS
of/IN
various/JJ
genetic/JJ
disorders/NNS
and/CC
cancer/NN
./.
====================
TEs/NNS
are/VBP
a/DT
subject/JJ
of/IN
interest/NN
worldwide/NN
,/,
not/RB
only/RB
in/IN
terms/NNS
of/IN
their/PRP$
clinical/JJ
aspects/NNS
but/CC
also/RB
in/IN
basic/JJ
research/NN
,/,
such/JJ
as/IN
evolutionary/JJ
tracking/VBG
./.
====================
Although/IN
active/JJ
TEs/NNS
contribute/VBP
to/TO
genetic/JJ
instability/NN
and/CC
disease/NN
states/NNS
,/,
non-long/JJ
terminal/JJ
repeat/NN
transposons/NNS
are/VBP
well/RB
studied/VBN
,/,
and/CC
their/PRP$
roles/NNS
in/IN
these/DT
processes/NNS
have/VBP
been/VBN
confirmed/VBN
./.
====================
In/IN
this/DT
review/NN
,/,
we/PRP
will/MD
give/VB
an/DT
overview/NN
of/IN
the/DT
importance/NN
of/IN
TEs/NNS
in/IN
studying/VBG
genome/NN
evolution/NN
and/CC
genetic/JJ
instability/NN
,/,
and/CC
we/PRP
suggest/VBP
that/IN
further/RB
in-depth/IN
studies/NNS
on/IN
the/DT
mechanisms/NNS
related/JJ
to/TO
these/DT
phenomena/NNS
will/MD
be/VB
useful/JJ
for/IN
both/DT
evolutionary/JJ
tracking/VBG
and/CC
clinical/JJ
diagnostics/NNS
./.
====================
Transposable/JJ
elements/NNS
(/(
TEs/NNS
)/)
are/VBP
DNA/NN
sequences/NNS
that/WDT
are/VBP
capable/JJ
of/IN
integrating/VBG
into/IN
the/DT
genome/NN
at/IN
a/DT
new/JJ
site/NN
within/IN
the/DT
cell/NN
of/IN
its/PRP$
origin/NN
./.
====================
Sometimes/NNS
,/,
the/DT
change/NN
in/IN
their/PRP$
positions/NNS
creates/VBZ
or/CC
reverses/VBZ
mutations/NNS
,/,
thereby/RB
altering/VBG
the/DT
cell/NN
's/POS
genotype/NN
./.
====================
Barbara/NN
McClintock/NN
's/POS
discovery/NN
of/IN
these/DT
``/NN
jumping/VBG
genes/NNS
''/CD
earned/JJ
her/RB
a/DT
Nobel/JJ
Prize/NN
in/IN
1983/CD
[/(
1/CD
]/)
./.
====================
TEs/NNS
are/VBP
prevalent/JJ
in/IN
all/DT
plants/NNS
and/CC
animals/NNS
./.
====================
In/IN
mammals/NNS
,/,
TEs/NNS
and/CC
their/PRP$
remnants/NNS
make/VBP
up/IN
almost/RB
half/NN
of/IN
the/DT
genome/NN
,/,
and/CC
in/IN
some/DT
plants/NNS
,/,
they/PRP
constitute/VBP
up/IN
to/TO
90/CD
%/NN
of/IN
the/DT
genome/NN
[/(
2/CD
]/)
./.
====================
TEs/NNS
consist/VBP
of/IN
two/CD
major/JJ
classes/NNS
:/:
DNA/NN
transposons/NNS
and/CC
retrotransposons/NNS
./.
====================
DNA/NN
transposons/NNS
are/VBP
capable/JJ
of/IN
moving/VBG
and/CC
inserting/JJ
into/IN
new/JJ
genomic/JJ
sites/NNS
[/(
3/CD
]/)
./.
====================
Although/IN
they/PRP
are/VBP
currently/RB
not/RB
mobile/JJ
in/IN
the/DT
human/JJ
genome/NN
,/,
they/PRP
were/VBD
active/JJ
during/IN
early/JJ
primate/JJ
evolution/NN
until/IN
~37/CD
million/NN
years/NNS
ago/NN
(/(
Mya/NN
)/)
[/(
4/CD
]/)
./.
====================
Retrotransposons/NNS
replicate/VBP
by/IN
forming/VBG
RNA/NN
intermediates/NNS
,/,
which/WDT
are/VBP
then/RB
reverse-transcribed/VBD
to/TO
make/VB
DNA/NN
sequences/NNS
and/CC
inserted/JJ
into/IN
new/JJ
genomic/JJ
locations/NNS
[/(
4/CD
]/)
./.
====================
Based/VBN
on/IN
the/DT
presence/NN
of/IN
long/JJ
terminal/JJ
repeats/NNS
(/(
LTRs/NNS
)/)
,/,
retrotransposons/NNS
are/VBP
further/RBR
classified/VBN
into/IN
two/CD
groups/NNS
:/:
LTR/NN
and/CC
non-LTR/NN
transposons/NNS
./.
====================
In/IN
humans/NNS
,/,
LTR/NN
elements/NNS
are/VBP
called/VBN
human/JJ
endogenous/JJ
retroviruses/NNS
(/(
HERVs/NNS
)/)
./.
====================
It/PRP
is/VBZ
estimated/VBN
that/DT
HERVs/NNS
inserted/VBN
into/IN
the/DT
human/JJ
genome/NN
>/JJR
25/CD
Mya/NN
[/(
5/CD
,/,
6/CD
]/)
./.
====================
Non-LTR/NN
retrotransposons/NNS
include/VBP
long/JJ
interspersed/JJ
element/NN
1/CD
(/(
LINE-1/NN
or/CC
L1/NN
)/)
,/,
Alu/NNP
,/,
and/CC
SVA/NN
elements/NNS
./.
====================
Studies/NNS
have/VBP
revealed/VBN
that/IN
these/DT
are/VBP
the/DT
only/RB
TEs/NNS
that/DT
are/VBP
currently/RB
active/JJ
in/IN
humans/NNS
[/(
7/CD
,/,
8/CD
,/,
9/CD
,/,
10/CD
,/,
11/CD
]/)
./.
====================
TEs/NNS
have/VBP
driven/VBN
genome/NN
evolution/NN
in/IN
multiple/JJ
ways/NNS
./.
====================
Retrotransposons/NNS
comprise/VBP
a/DT
large/JJ
proportion/NN
of/IN
the/DT
genome/NN
,/,
especially/RB
in/IN
plants/NNS
and/CC
mammals/NNS
./.
====================
The/DT
effect/NN
of/IN
the/DT
increase/NN
in/IN
retrotransposons/NNS
has/VBZ
been/VBN
tolerated/VBN
during/IN
evolution/NN
./.
====================
Accumulating/VBG
literature/NN
has/VBZ
proven/VBN
that/DT
mobile/JJ
elements/NNS
are/VBP
useful/JJ
tools/NNS
for/IN
studying/VBG
genome/NN
evolution/NN
and/CC
gene/NN
function/NN
[/(
12/CD
]/)
./.
====================
A/DT
comparative/JJ
analysis/NN
has/VBZ
shown/VBN
that/IN
the/DT
human/JJ
genome/NN
makes/VBZ
655/CD
perfect/NN
full-length/JJ
matches/NNS
with/IN
vertebrate/JJ
TEs/NNS
./.
====================
TE/DT
insertions/NNS
have/VBP
been/VBN
shown/VBN
to/TO
have/VB
many/JJ
effects/NNS
,/,
such/JJ
as/IN
regulation/NN
of/IN
gene/NN
expression/NN
,/,
increased/VBD
recombination/NN
rate/NN
,/,
and/CC
unequal/JJ
crossover/RB
./.
====================
TE/DT
insertions/NNS
have/VBP
caused/VBN
many/JJ
effective/JJ
changes/NNS
in/IN
the/DT
human/JJ
genome/NN
,/,
and/CC
the/DT
selected/VBN
changes/NNS
have/VBP
been/VBN
responsible/JJ
for/IN
the/DT
evolution/NN
of/IN
the/DT
human/JJ
lineage/NN
[/(
13/CD
]/)
./.
====================
The/DT
human/JJ
genome/NN
contains/VBZ
many/JJ
recently/RB
inserted/VBN
active/JJ
TEs/NNS
,/,
such/JJ
as/IN
AluYa5/NN
,/,
AluYb8/NN
,/,
and/CC
AluYc1/NN
./.
====================
Alu/RB
elements/NNS
are/VBP
a/DT
family/NN
of/IN
primate-specific/JJ
short/JJ
interspersed/JJ
DNA/NN
elements/NNS
./.
====================
Various/JJ
studies/NNS
have/VBP
proposed/VBN
that/IN
Alu/NNP
element/NN
insertions/NNS
have/VBP
created/VBN
many/JJ
variants/NNS
that/DT
can/MD
potentially/RB
be/VB
used/VBN
as/IN
DNA/NN
markers/NNS
in/IN
human/JJ
population/NN
studies/NNS
,/,
as/IN
well/RB
as/IN
in/IN
forensic/JJ
analyses/NNS
./.
====================
Kass/NN
et/FW
al/JJ
./.
====================
[/(
14/CD
]/)
have/VBP
identified/VBN
an/DT
Alu-based/JJ
polymorphism/NN
that/WDT
consists/VBZ
of/IN
four/CD
alleles/NNS
,/,
from/IN
which/WDT
the/DT
evolutionary/JJ
order/NN
can/MD
be/VB
predicted/VBN
./.
====================
The/DT
effects/NNS
of/IN
TEs/NNS
on/IN
genetic/JJ
instability/NN
and/CC
human/JJ
diseases/NNS
have/VBP
not/RB
been/VBN
thoroughly/RB
studied/VBN
./.
====================
The/DT
mobile/JJ
property/NN
of/IN
TEs/NNS
is/VBZ
the/DT
reason/NN
for/IN
their/PRP$
mutational/JJ
potential/JJ
./.
====================
TE/DT
insertions/NNS
may/MD
create/VB
a/DT
broad/JJ
range/NN
of/IN
effects/NNS
on/IN
humans/NNS
,/,
ranging/VBG
from/IN
silent/JJ
mutations/NNS
to/TO
alternative/JJ
splicing/NN
./.
====================
Both/DT
insertions/NNS
and/CC
excisions/NNS
of/IN
TEs/NNS
can/MD
cause/VB
genomic/JJ
instability/NN
,/,
thus/RB
causing/VBG
many/JJ
human/JJ
diseases/NNS
,/,
including/VBG
genetic/JJ
disorders/NNS
,/,
psychiatric/JJ
problems/NNS
,/,
and/CC
cancer/NN
[/(
15/CD
,/,
16/CD
,/,
17/CD
,/,
18/CD
,/,
19/CD
,/,
20/CD
,/,
21/CD
]/)
./.
====================
Furthermore/RB
,/,
TE/NN
insertions/NNS
may/MD
result/VB
in/IN
insertional/JJ
mutations/NNS
,/,
non-allelic/JJ
homologous/JJ
recombination/NN
(/(
NAHR/NN
)/)
,/,
creation/NN
of/IN
novel/JJ
regulatory/JJ
sequences/NNS
,/,
and/CC
epigenetic/JJ
changes/NNS
[/(
22/CD
]/)
./.
====================
A/DT
large/JJ
number/NN
of/IN
human/JJ
diseases/NNS
that/IN
are/VBP
associated/VBN
with/IN
NAHR/NN
between/IN
Alu/NN
elements/NNS
have/VBP
been/VBN
reported/VBN
[/(
22/CD
]/)
./.
====================
Technical/JJ
advances/NNS
have/VBP
helped/VBN
to/TO
detect/VB
TE-associated/JJ
diseases/NNS
and/CC
develop/VBP
novel/JJ
biomarkers/NNS
for/IN
clinical/JJ
diagnostics/NNS
./.
====================
Computational/JJ
tools/NNS
have/VBP
been/VBN
developed/VBN
to/TO
study/VB
the/DT
dynamics/NNS
of/IN
transposition/NN
at/IN
a/DT
population/NN
level/NN
,/,
thus/RB
providing/VBG
critical/JJ
insights/NNS
into/IN
the/DT
mechanisms/NNS
behind/VBP
genome/NN
evolution/NN
./.
====================
Finally/RB
,/,
combining/VBG
the/DT
genomic/JJ
materials/NNS
from/IN
diverse/JJ
individuals/NNS
followed/VBN
by/IN
high-throughput/JJ
sequencing/NN
can/MD
enhance/VB
the/DT
significance/NN
of/IN
characterizing/VBG
genomic/JJ
polymorphisms/NNS
in/IN
a/DT
population/NN
[/(
23/CD
]/)
./.
====================
In/IN
this/DT
review/NN
,/,
we/PRP
will/MD
provide/VB
updates/VBZ
on/IN
our/PRP$
current/JJ
understanding/NN
of/IN
the/DT
roles/NNS
of/IN
TEs/NNS
in/IN
genome/NN
evolution/NN
and/CC
genetic/JJ
instability/NN
./.
====================
Further/RB
,/,
we/PRP
focus/VBP
on/IN
how/WRB
their/PRP$
activity/NN
affects/VBZ
gene/NN
expression/NN
and/CC
causes/VBZ
disease/NN
states/NNS
in/IN
human/JJ
beings/NNS
./.
====================
Brain/NN
evolution/NN
is/VBZ
an/DT
important/JJ
process/NN
that/WDT
accelerated/VBN
the/DT
evolution/NN
of/IN
humans/NNS
./.
====================
This/DT
occurred/VBD
due/IN
to/TO
natural/JJ
selection/NN
and/CC
genomic/JJ
variation/NN
,/,
a/DT
major/JJ
source/NN
of/IN
which/WDT
has/VBZ
been/VBN
TE/NN
insertions/NNS
./.
====================
TE/DT
insertions/NNS
contributed/VBD
markedly/RB
to/TO
variation/NN
and/CC
increased/VBD
the/DT
speed/JJ
of/IN
evolution/NN
[/(
24/CD
,/,
25/CD
,/,
26/CD
]/)
./.
====================
Furthermore/RB
,/,
they/PRP
increase/VBP
the/DT
recombination/NN
rate/NN
,/,
in/IN
addition/NN
to/TO
affecting/VBG
genes/NNS
and/CC
their/PRP$
expression/NN
[/(
24/CD
,/,
26/CD
]/)
./.
====================
From/IN
an/DT
evolutionary/JJ
perspective/JJ
,/,
humans/NNS
are/VBP
unique/JJ
in/IN
the/DT
speed/JJ
of/IN
evolution/NN
and/CC
the/DT
number/NN
and/CC
activity/NN
of/IN
TEs/NNS
./.
====================
It/PRP
is/VBZ
proposed/VBN
that/IN
the/DT
high/JJ
frequency/NN
of/IN
TE/NN
insertions/NNS
is/VBZ
responsible/JJ
at/IN
least/JJS
in/IN
part/NN
for/IN
the/DT
rapid/JJ
evolution/NN
of/IN
humans/NNS
./.
====================
It/PRP
is/VBZ
speculated/VBN
that/DT
some/DT
sets/NNS
of/IN
genes/NNS
might/MD
have/VBP
been/VBN
activated/VBN
or/CC
suppressed/VBD
due/JJ
to/TO
variations/NNS
caused/VBD
by/IN
TE/NN
insertions/NNS
,/,
which/WDT
in/IN
turn/NN
increased/VBD
the/DT
chances/NNS
for/IN
evolution/NN
[/(
13/CD
]/)
./.
====================
There/EX
has/VBZ
been/VBN
a/DT
prominent/JJ
impact/NN
of/IN
retrotransposons/NNS
on/IN
human/JJ
evolution/NN
at/IN
the/DT
genomic/JJ
level/NN
./.
====================
Retrotransposons/NNS
have/VBP
shaped/VBN
human/JJ
evolution/NN
at/IN
the/DT
RNA/NN
level/NN
through/IN
various/JJ
mechanisms/NNS
,/,
such/JJ
as/IN
modulation/NN
of/IN
gene/NN
expression/NN
,/,
RNA/NN
editing/VBG
,/,
and/CC
epigenetic/JJ
regulation/NN
[/(
27/CD
]/)
./.
====================
LTR/NN
retrotransposons/NNS
====================
In/IN
humans/NNS
,/,
LTR/NN
retrotransposons/NNS
are/VBP
called/VBN
HERVs/NNS
(/(
Fig/NN
./.
====================
1/CD
)/)
,/,
which/WDT
constitute/VBP
5/CD
%/NN
of/IN
the/DT
genome/NN
./.
====================
The/DT
human/JJ
genome/NN
shows/VBZ
99/CD
%/NN
similarity/NN
with/IN
chimpanzees/NNS
and/CC
bonobos/NN
./.
====================
Hence/RB
,/,
the/DT
differences/NNS
between/IN
these/DT
species/NNS
are/VBP
likely/JJ
to/TO
be/VB
in/IN
regulatory/JJ
sequences/NNS
:/:
promoters/NNS
,/,
enhancers/NNS
,/,
polyadenylation/NN
signals/NNS
,/,
and/CC
transcription/NN
factor/NN
(/(
TF/NN
)/)
binding/NN
sites/NNS
./.
====================
The/DT
LTRs/NNS
of/IN
HERVs/NNS
help/VB
in/IN
regulating/VBG
the/DT
expression/NN
of/IN
nearby/JJ
genes/NNS
./.
====================
The/DT
active/JJ
human-specific/JJ
LTRs/NNS
that/WDT
have/VBP
been/VBN
identified/VBN
belong/IN
to/TO
the/DT
HERV-K/NN
family/NN
./.
====================
It/PRP
is/VBZ
proposed/VBN
that/IN
some/DT
of/IN
these/DT
endogenous/JJ
retroviruses/NNS
may/MD
have/VB
integrated/VBN
into/IN
regulatory/JJ
regions/NNS
of/IN
the/DT
human/JJ
genome/NN
and/CC
that/IN
they/PRP
eventually/RB
contributed/VBD
to/TO
human/JJ
evolution/NN
[/(
28/CD
]/)
./.
====================
Khodosevich/JJ
et/FW
al/JJ
./.
====================
[/(
28/CD
]/)
suggested/VBD
that/IN
regulatory/JJ
sequences/NNS
found/VBN
in/IN
retroviral/JJ
LTRs/NNS
may/MD
alter/VB
the/DT
expression/NN
of/IN
(/(
or/CC
even/RB
inactivate/VBP
)/)
adjacent/JJ
genes/NNS
./.
====================
On/IN
the/DT
other/JJ
hand/NN
,/,
HERV/NN
insertion/NN
may/MD
benefit/VB
the/DT
host/NN
,/,
for/IN
example/NN
,/,
by/IN
reverting/VBG
harmful/JJ
mutation/NN
[/(
28/CD
]/)
./.
====================
Non-LTR/NN
retrotransposon/NN
====================
Human/JJ
non-LTR/NN
retroposons/NNS
include/VBP
both/CC
active/JJ
(/(
L1/NN
,/,
Alu/NNP
,/,
and/CC
SVA/NN
)/)
and/CC
inactive/JJ
elements/NNS
(/(
L2/NN
and/CC
mammalian-wide/JJ
interspersed/VBN
repeat/NN
)/)
./.
====================
Although/IN
more/RBR
than/IN
500,000/CD
copies/NNS
of/IN
L1/NN
elements/NNS
are/VBP
found/VBN
in/IN
the/DT
human/JJ
genome/NN
,/,
only/RB
100/CD
copies/NNS
are/VBP
known/VBN
to/TO
be/VB
intact/JJ
[/(
29/CD
]/)
./.
====================
An/DT
intact/JJ
L1/NN
element/NN
is/VBZ
approximately/RB
6/CD
kilobases/NNS
(/(
kb/NN
)/)
in/IN
length/NN
,/,
with/IN
a/DT
5/CD
'/``
untranslated/JJ
region/NN
(/(
UTR/NN
)/)
containing/VBG
an/DT
internal/JJ
RNA/NN
polymerase/NN
II/CD
promoter/NN
,/,
two/CD
open/JJ
reading/NN
frames/NNS
(/(
ORF1/NN
and/CC
ORF2/NN
)/)
,/,
and/CC
a/DT
3/CD
'/``
UTR/NN
(/(
Fig/NN
./.
====================
1/CD
)/)
[/(
29/CD
,/,
30/CD
]/)
./.
====================
L1/NN
elements/NNS
are/VBP
the/DT
only/RB
autonomous/JJ
TEs/NNS
in/IN
the/DT
human/JJ
genome/NN
because/IN
of/IN
their/PRP$
retrotransposition/NN
property/NN
,/,
called/VBN
target-primed/VBN
reverse/JJ
transcription/NN
[/(
27/CD
]/)
./.
====================
Alu/RB
elements/NNS
are/VBP
often/RB
called/VBN
``/NN
a/DT
parasite/JJ
's/POS
parasite/NN
,/,
''/NNP
because/IN
they/PRP
do/VBP
not/RB
code/VB
for/IN
a/DT
polymerase/NN
and/CC
,/,
hence/RB
,/,
are/VBP
non-autonomous/JJ
in/IN
nature/NN
./.
====================
Alu/RB
elements/NNS
depend/VBP
on/IN
L1/NN
elements/NNS
for/IN
retrotransposition/NN
machinery/NN
[/(
31/CD
,/,
32/CD
,/,
33/CD
]/)
./.
====================
However/RB
,/,
they/PRP
are/VBP
considered/VBN
the/DT
most/JJS
successful/JJ
TEs/NNS
in/IN
the/DT
human/JJ
genome/NN
in/IN
terms/NNS
of/IN
copy/NN
number/NN
[/(
27/CD
]/)
./.
====================
An/DT
intact/JJ
SVA/NN
element/NN
is/VBZ
approximately/RB
2/CD
kb/NN
in/IN
length/NN
,/,
which/WDT
includes/VBZ
a/DT
hexamer/NN
repeat/NN
,/,
an/DT
Alu-like/JJ
region/NN
,/,
a/DT
variable/JJ
number/NN
of/IN
tandem/JJ
repeats/NNS
,/,
and/CC
a/DT
HERV-K10-like/JJ
sequence/NN
./.
====================
SVA/NN
elements/NNS
are/VBP
also/RB
non-autonomous/JJ
and/CC
most/JJS
likely/RB
depend/VBP
on/IN
L1/NN
retrotransposition/NN
machinery/NN
[/(
34/CD
,/,
35/CD
]/)
./.
====================
Two/CD
key/JJ
features/NNS
of/IN
non-LTR/NN
retrotransposons/NNS
that/DT
control/VBP
retrotransposition/NN
activity/NN
are/VBP
high/JJ
copy/NN
number/NN
and/CC
continued/JJ
activity/NN
over/IN
millions/NNS
of/IN
years/NNS
[/(
5/CD
,/,
27/CD
]/)
./.
====================
From/IN
an/DT
evolutionary/JJ
perspective/JJ
,/,
the/DT
observed/VBN
uniqueness/IN
of/IN
non-LTR/NN
retrotransposons/NNS
is/VBZ
due/JJ
to/TO
their/PRP$
vertical/JJ
transfer/NN
in/IN
both/DT
primates/NNS
and/CC
mammals/NNS
[/(
4/CD
,/,
5/CD
,/,
36/CD
]/)
./.
====================
Amplification/NN
rates/NNS
among/IN
non-LTR/NN
retrotransposons/NNS
are/VBP
not/RB
uniform/JJ
(/(
Alu/NNP
,/,
40/CD
Mya/NN
;/:
L1/NN
,/,
12-40/CD
Mya/NN
;/:
SVA/NN
,/,
6/CD
Mya/NN
)/)
[/(
27/CD
]/)
./.
====================
Among/IN
non-LTR/NN
retrotransposons/NNS
,/,
Alu/NNP
elements/NNS
are/VBP
the/DT
most/JJS
thoroughly/RB
studied/VBN
in/IN
relation/NN
to/TO
evolution/NN
./.
====================
Alu/RB
repeats/NNS
may/MD
cause/VB
genomic/JJ
diversity/NN
in/IN
various/JJ
ways/NNS
./.
====================
Their/PRP$
amplification/NN
has/VBZ
enabled/VBN
them/PRP
to/TO
become/VB
the/DT
largest/JJS
family/NN
of/IN
mobile/JJ
elements/NNS
in/IN
the/DT
human/JJ
genome/NN
./.
====================
It/PRP
is/VBZ
estimated/VBN
that/DT
thousands/VBZ
of/IN
Alu/JJ
elements/NNS
have/VBP
integrated/VBN
into/IN
the/DT
human/JJ
genome/NN
since/IN
the/DT
divergence/NN
of/IN
humans/NNS
and/CC
African/JJ
apes/NNS
[/(
37/CD
,/,
38/CD
,/,
39/CD
,/,
40/CD
]/)
./.
====================
Although/IN
some/DT
Alu/NN
insertions/NNS
have/VBP
caused/VBN
harmful/JJ
mutations/NNS
,/,
most/JJS
have/VBP
contributed/VBN
to/TO
genetic/JJ
diversity/NN
[/(
8/CD
]/)
./.
====================
Moreover/RB
,/,
Alu/NNP
repeats/NNS
have/VBP
also/RB
influenced/VBD
the/DT
accumulation/NN
of/IN
single-nucleotide/JJ
polymorphisms/NNS
in/IN
the/DT
genome/NN
[/(
30/CD
,/,
40/CD
,/,
41/CD
]/)
./.
====================
From/IN
previous/JJ
reports/NNS
,/,
it/PRP
is/VBZ
evident/JJ
that/IN
most/JJS
of/IN
the/DT
recent/JJ
Alu/NNP
insertions/NNS
are/VBP
the/DT
source/NN
of/IN
genetic/JJ
variations/NNS
,/,
which/WDT
have/VBP
been/VBN
useful/JJ
for/IN
studying/VBG
both/CC
the/DT
relationships/NNS
between/IN
populations/NNS
and/CC
the/DT
evolution/NN
and/CC
organization/NN
of/IN
tandem-arrayed/VBN
gene/NN
families/NNS
[/(
37/CD
,/,
38/CD
,/,
39/CD
,/,
40/CD
]/)
./.
====================
Batzer/NN
and/CC
Deninger/NN
[/(
42/CD
]/)
suggested/VBD
that/IN
the/DT
Alu/NN
insertion/NN
,/,
in/IN
relation/NN
to/TO
genetic/JJ
variation/NN
,/,
may/MD
also/RB
be/VB
useful/JJ
in/IN
generating/VBG
species-specific/JJ
genetic/JJ
markers/NNS
./.
====================
TEs/NNS
can/MD
cause/VB
genomic/JJ
instability/NN
either/CC
by/IN
insertions/NNS
or/CC
by/IN
rearrangements/NNS
in/IN
the/DT
genome/NN
./.
====================
Notably/RB
,/,
structural/JJ
variations/NNS
in/IN
the/DT
human/JJ
genome/NN
are/VBP
the/DT
primary/JJ
cause/VBP
of/IN
inter-individual/JJ
variability/NN
./.
====================
Structural/JJ
variations/NNS
include/VBP
insertion/NN
,/,
deletion/NN
,/,
inversion/NN
,/,
duplication/NN
,/,
and/CC
translocation/NN
./.
====================
The/DT
characteristics/NNS
of/IN
TEs/NNS
,/,
such/JJ
as/IN
abundance/RB
in/IN
the/DT
genome/NN
,/,
high/JJ
sequence/NN
identity/NN
,/,
and/CC
ability/NN
to/TO
move/VB
,/,
make/VBP
them/PRP
major/JJ
contributors/NNS
to/TO
genomic/JJ
instability/NN
[/(
5/CD
,/,
27/CD
,/,
43/CD
]/)
./.
====================
Recent/JJ
studies/NNS
have/VBP
revealed/VBN
the/DT
implications/NNS
of/IN
TEs/NNS
in/IN
genomic/JJ
instability/NN
and/CC
human/JJ
genome/NN
evolution/NN
[/(
44/CD
]/)
./.
====================
Mutations/NNS
associated/VBN
with/IN
TE/NN
insertions/NNS
are/VBP
well/RB
studied/VBN
,/,
and/CC
approximately/RB
0.3/CD
%/NN
of/IN
all/DT
mutations/NNS
are/VBP
caused/VBN
by/IN
retrotransposon/NN
insertions/NNS
[/(
27/CD
]/)
./.
====================
Such/JJ
insertions/NNS
can/MD
be/VB
deleterious/JJ
by/IN
disrupting/VBG
the/DT
regulatory/JJ
sequences/NNS
of/IN
a/DT
gene/NN
./.
====================
When/WRB
a/DT
TE/JJ
inserts/NNS
within/IN
an/DT
exon/NN
,/,
it/PRP
may/MD
change/VB
the/DT
ORF/NN
,/,
such/JJ
that/IN
it/PRP
codes/VBZ
for/IN
an/DT
aberrant/JJ
peptide/NN
,/,
or/CC
it/PRP
may/MD
even/RB
cause/VBP
missense/NN
or/CC
nonsense/JJ
mutations/NNS
./.
====================
On/IN
the/DT
other/JJ
hand/NN
,/,
if/IN
it/PRP
is/VBZ
inserted/VBN
into/IN
an/DT
intronic/JJ
region/NN
,/,
it/PRP
may/MD
cause/VB
an/DT
alternative/JJ
splicing/NN
event/NN
by/IN
introducing/VBG
novel/JJ
splice/NN
sites/NNS
,/,
disrupting/VBG
the/DT
canonical/JJ
splice/NN
site/NN
,/,
or/CC
introducing/VBG
a/DT
polyadenylation/NN
signal/NN
[/(
8/CD
,/,
9/CD
,/,
10/CD
,/,
11/CD
,/,
42/CD
,/,
43/CD
]/)
./.
====================
In/IN
some/DT
instances/NNS
,/,
TE/NN
insertion/NN
into/IN
intronic/JJ
regions/NNS
can/MD
cause/VB
mRNA/NN
destabilization/NN
,/,
thereby/RB
reducing/VBG
gene/NN
expression/NN
[/(
45/CD
]/)
./.
====================
Similarly/RB
,/,
some/DT
studies/NNS
have/VBP
suggested/VBN
that/IN
TE/NN
insertion/NN
into/IN
the/DT
5/CD
'/``
or/CC
3/CD
'/``
region/NN
of/IN
a/DT
gene/NN
may/MD
alter/VB
its/PRP$
expression/NN
[/(
46/CD
,/,
47/CD
,/,
48/CD
]/)
./.
====================
Thus/RB
,/,
such/JJ
a/DT
change/NN
in/IN
gene/NN
expression/NN
may/MD
,/,
in/IN
turn/NN
,/,
change/NN
the/DT
equilibrium/NN
of/IN
regulatory/JJ
networks/NNS
and/CC
result/NN
in/IN
disease/NN
conditions/NNS
(/(
reviewed/VBD
in/IN
Konkel/NN
and/CC
Batzer/NN
[/(
43/CD
]/)
)/)
./.
====================
The/DT
currently/RB
active/JJ
non-LTR/NN
transposons/NNS
,/,
L1/NN
,/,
SVA/NN
,/,
and/CC
Alu/FW
,/,
are/VBP
reported/VBN
to/TO
be/VB
the/DT
causative/JJ
factors/NNS
of/IN
many/JJ
genetic/JJ
disorders/NNS
,/,
such/JJ
as/IN
hemophilia/NN
,/,
Apert/RB
syndrome/NN
,/,
familial/JJ
hypercholesterolemia/NN
,/,
and/CC
colon/NN
and/CC
breast/NN
cancer/NN
(/(
Table/JJ
1/CD
)/)
[/(
8/CD
,/,
10/CD
,/,
11/CD
,/,
27/CD
]/)
./.
====================
Among/IN
the/DT
reported/VBN
TE-mediated/JJ
genetic/JJ
disorders/NNS
,/,
X-linked/JJ
diseases/NNS
are/VBP
more/RBR
abundant/JJ
than/IN
autosomal/JJ
diseases/NNS
[/(
11/CD
,/,
27/CD
,/,
45/CD
]/)
,/,
most/JJS
of/IN
which/WDT
are/VBP
caused/VBN
by/IN
L1/NN
insertions/NNS
./.
====================
However/RB
,/,
the/DT
phenomenon/NN
behind/VBP
L1/NN
and/CC
X-linked/JJ
genetic/JJ
disorders/NNS
has/VBZ
not/RB
yet/RB
been/VBN
revealed/VBN
./.
====================
The/DT
breast/NN
cancer/NN
2/CD
(/(
BRCA2/NN
)/)
gene/NN
,/,
associated/VBN
with/IN
breast/NN
and/CC
ovarian/JJ
cancers/NNS
,/,
has/VBZ
been/VBN
reported/VBN
to/TO
be/VB
disrupted/VBN
by/IN
multiple/JJ
non-LTR/NN
TE/NN
insertions/NNS
[/(
9/CD
,/,
18/CD
,/,
49/CD
]/)
./.
====================
There/EX
are/VBP
some/DT
reports/NNS
that/IN
the/DT
same/JJ
location/NN
of/IN
a/DT
gene/NN
may/MD
undergo/VB
multiple/JJ
insertions/NNS
(/(
e.g./FW
,/,
Alu/NNP
and/CC
L1/NN
insertions/NNS
in/IN
the/DT
adenomatous/JJ
polyposis/NN
coli/FW
gene/NN
)/)
(/(
Table/JJ
1/CD
)/)
./.
====================
It/PRP
has/VBZ
also/RB
been/VBN
proposed/VBN
that/IN
inverted/VBD
repeats/NNS
are/VBP
likely/JJ
to/TO
be/VB
hotspots/NNS
of/IN
genomic/JJ
instability/NN
[/(
50/CD
]/)
./.
====================
Closely/RB
occurring/VBG
Alu/NN
repeats/NNS
form/VBP
hairpin/NN
structures/NNS
that/DT
are/VBP
prone/NN
to/TO
double-strand/JJ
breaks/NNS
(/(
DSBs/NNS
)/)
and/CC
excision/NN
[/(
50/CD
,/,
51/CD
]/)
./.
====================
In/IN
addition/NN
,/,
de/FW
novo/FW
Alu/NN
insertions/NNS
may/MD
create/VB
new/JJ
inverted/VBN
repeats/NNS
that/WDT
result/VBP
in/IN
rearrangements/NNS
in/IN
future/JJ
generations/NNS
[/(
43/CD
]/)
./.
====================
Due/IN
to/TO
the/DT
abundance/NN
of/IN
TEs/NNS
in/IN
the/DT
human/JJ
genome/NN
,/,
the/DT
probability/NN
of/IN
TE-mediated/JJ
NAHR/NN
translocations/NNS
is/VBZ
high/JJ
./.
====================
Kolomietz/NN
et/FW
al/JJ
./.
====================
[/(
52/CD
]/)
reported/VBD
that/IN
Alu/NN
elements/NNS
are/VBP
often/RB
found/VBN
in/IN
and/CC
around/IN
the/DT
breakage/NN
points/NNS
of/IN
translocations/NNS
and/CC
result/NN
in/IN
diseases/NNS
[/(
53/CD
]/)
./.
====================
Some/DT
studies/NNS
have/VBP
analyzed/VBN
the/DT
human/JJ
genome/NN
using/VBG
the/DT
chimpanzee/NN
reference/VBP
genome/NN
and/CC
found/VBD
that/IN
deletions/NNS
that/IN
are/VBP
caused/VBN
by/IN
Alu-mediated/JJ
NAHRs/NNS
are/VBP
9/CD
times/NNS
more/RBR
frequent/JJ
than/IN
L1-mediated/JJ
NAHRs/NNS
in/IN
the/DT
human/JJ
genome/NN
[/(
54/CD
,/,
55/CD
]/)
./.
====================
Alu-mediated/JJ
NAHRs/NNS
are/VBP
known/VBN
to/TO
be/VB
associated/VBN
with/IN
various/JJ
genetic/JJ
disorders/NNS
and/CC
cancer/NN
(/(
Table/JJ
1/CD
)/)
[/(
8/CD
,/,
10/CD
]/)
./.
====================
L1/NN
endonuclease/NN
creates/VBZ
abundant/JJ
DSBs/NNS
that/DT
are/VBP
required/VBN
for/IN
retrotransposition/NN
in/IN
mammalian/JJ
cells/NNS
and/CC
eventually/RB
contribute/VBP
to/TO
genomic/JJ
instability/NN
[/(
56/CD
]/)
./.
====================
However/RB
,/,
it/PRP
has/VBZ
been/VBN
difficult/JJ
to/TO
define/VB
this/DT
in/IN
an/DT
experimental/JJ
condition/NN
,/,
as/IN
physiological/JJ
conditions/NNS
can/MD
not/RB
be/VB
simulated/JJ
in/IN
vitro/FW
./.
====================
Moreover/RB
,/,
it/PRP
is/VBZ
also/RB
difficult/JJ
to/TO
distinguish/VB
DSBs/NNS
caused/VBD
by/IN
L1/NN
from/IN
DSBs/NNS
caused/VBD
by/IN
other/JJ
mechanisms/NNS
in/IN
vivo/FW
[/(
44/CD
,/,
56/CD
]/)
./.
====================
From/IN
recent/JJ
studies/NNS
,/,
it/PRP
is/VBZ
apparent/JJ
that/IN
the/DT
methylation/NN
state/NN
of/IN
DNA/NN
is/VBZ
associated/VBN
with/IN
cancer/NN
[/(
57/CD
]/)
./.
====================
TEs-in/JJ
particular/JJ
,/,
the/DT
promoters/NNS
of/IN
L1/NN
elements-are/JJ
reported/VBD
to/TO
be/VB
demethylated/VBN
in/IN
cancer/NN
cells/NNS
[/(
58/CD
,/,
59/CD
]/)
./.
====================
On/IN
the/DT
other/JJ
hand/NN
,/,
the/DT
methylation/NN
of/IN
retrotransposons/NNS
is/VBZ
supposed/VBN
to/TO
be/VB
a/DT
defense/NN
mechanism/NN
against/IN
retrotransposition/NN
in/IN
somatic/JJ
cells/NNS
[/(
60/CD
]/)
./.
====================
It/PRP
has/VBZ
also/RB
been/VBN
reported/VBN
by/IN
some/DT
studies/NNS
that/IN
the/DT
L1/NN
transcription/NN
rate/NN
is/VBZ
increased/VBN
in/IN
hypomethylated/JJ
cancer/NN
cells/NNS
[/(
58/CD
,/,
61/CD
]/)
./.
====================
Demethylation/NN
of/IN
TE/NN
promoters/NNS
may/MD
result/VB
in/IN
their/PRP$
activation/NN
,/,
which/WDT
in/IN
turn/NN
could/MD
modify/VB
the/DT
TF/NN
level/NN
in/IN
the/DT
cell/NN
./.
====================
It/PRP
is/VBZ
possible/JJ
that/IN
such/JJ
changes/NNS
in/IN
TF/NN
levels/NNS
lead/VBP
to/TO
alterations/NNS
in/IN
global/JJ
gene/NN
expression/NN
[/(
57/CD
]/)
./.
====================
In/IN
addition/NN
,/,
demethylation/NN
may/MD
result/VB
in/IN
the/DT
activation/NN
of/IN
the/DT
L1/NN
antisense/JJ
promoter/NN
,/,
which/WDT
may/MD
eventually/RB
produce/VBP
cancerassociated/JJ
chimeric/JJ
transcripts/NNS
[/(
62/CD
,/,
63/CD
]/)
./.
====================
Taken/VBN
together/RB
,/,
the/DT
mechanisms/NNS
discussed/VBN
above/IN
have/VBP
demonstrated/VBN
the/DT
considerable/JJ
impact/NN
of/IN
TEs/NNS
on/IN
human/JJ
genome/NN
evolution/NN
,/,
genetic/JJ
instability/NN
,/,
and/CC
disease/NN
occurrence/NN
./.
====================
There/EX
has/VBZ
been/VBN
a/DT
recent/JJ
increase/NN
in/IN
studies/NNS
demonstrating/VBG
the/DT
roles/NNS
of/IN
TEs/NNS
in/IN
multiple/JJ
molecular/JJ
processes/NNS
./.
====================
Importantly/RB
,/,
several/JJ
studies/NNS
have/VBP
found/VBN
an/DT
association/NN
between/IN
TEs/NNS
and/CC
cancer/NN
conditions/NNS
./.
====================
Technological/JJ
developments/NNS
have/VBP
led/VBN
to/TO
promising/VBG
techniques/NNS
(/(
e.g./FW
,/,
next-generation/NN
sequencing/NN
)/)
that/WDT
will/MD
assist/VB
researchers/NNS
in/IN
studying/VBG
,/,
understanding/VBG
,/,
and/CC
confirming/VBG
the/DT
role/NN
of/IN
TEs/NNS
in/IN
genetic/JJ
instability/NN
and/CC
diseases/NNS
./.
====================
Such/JJ
progress/VBP
may/MD
lead/VB
to/TO
the/DT
development/NN
of/IN
novel/JJ
therapeutic/JJ
strategies/NNS
in/IN
the/DT
near/JJ
future/JJ
,/,
such/JJ
as/IN
personalized/VBN
gene/NN
therapy/NN
for/IN
the/DT
treatment/NN
of/IN
genetic/JJ
disorders/NNS
./.
====================
The/DT
clinical/JJ
community/NN
has/VBZ
already/RB
realized/VBN
the/DT
importance/NN
of/IN
personalized/VBN
cancer/NN
treatments/NNS
and/CC
is/VBZ
moving/VBG
toward/IN
excellence/IN
in/IN
such/JJ
treatment/NN
strategies/NNS
./.
====================
Therefore/RB
,/,
we/PRP
believe/VBP
that/IN
in-depth/IN
studies/NNS
on/IN
the/DT
role/NN
(/(
s/NNS
)/)
of/IN
TEs/NNS
in/IN
evolution/NN
,/,
the/DT
epigenetic/JJ
control/NN
of/IN
gene/NN
expression/NN
,/,
and/CC
clinical/JJ
aspects/NNS
will/MD
be/VB
of/IN
paramount/JJ
importance/NN
in/IN
uncovering/VBG
novel/JJ
mechanisms/NNS
that/WDT
can/MD
be/VB
targeted/VBN
for/IN
therapeutic/JJ
intervention/NN
./.
====================
Classification/NN
and/CC
structure/NN
of/IN
transposable/JJ
elements/NNS
./.
====================
DRs/NNS
,/,
direct/JJ
repeats/NNS
;/:
ITRs/NNS
,/,
inverted/VBN
terminal/JJ
repeats/NNS
;/:
TSD/NN
,/,
tandem/JJ
site/NN
duplication/NN
;/:
LTRs/NNS
,/,
long/JJ
terminal/JJ
repeats/NNS
;/:
UTRs/NNS
,/,
untranslated/JJ
region/NN
;/:
ORF/NN
,/,
open/JJ
reading/NN
frame/NN
;/:
L/NN
,/,
left/NN
;/:
R/NN
,/,
right/JJ
;/:
SINE/NN
,/,
short/JJ
interspersed/VBN
nuclear/JJ
element/NN
./.
====================
Disease/NN
conditions/NNS
associated/VBN
with/IN
transposable/JJ
element/NN
(/(
TE/NN
)/)
insertions/NNS
====================
